Furthermore, we investigated the effects of CDKN2A modulation on key cell cycle regulators, such as p16INK4a, p14ARF, p53, and p21, to gain mechanistic insights into the tumor-suppressive function of CDKN2A in glioblastoma. This evidence concerns the gene TP53 and glioblastoma.